Coagulation factor VIIa Recombinant Human

Identification

Summary

Coagulation factor VIIa Recombinant Human is a form of recombinant human coagulation Factor VII used to treat hemophilia A and B.

Brand Names
Niastase RT, Novoseven, Sevenfact
Generic Name
Coagulation factor VIIa Recombinant Human
DrugBank Accession Number
DB00036
Background

Recombinant human coagulation Factor VIIa (rFVIIa), intended for promoting hemostasis by activating the extrinsic pathway of the coagulation cascade. NovoSeven is a vitamin K-dependent glycoprotein consisting of 406 amino acid residues. Cloned and expressed in hamster kidney cells, the protein is catalytically active in a two-chain form.

Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Blood factors
Protein Structure
Db00036
Protein Chemical Formula
C1972H3076N560O597S28
Protein Average Weight
45079.1 Da
Sequences
>DB00036 sequence
ANAFLEELRPGSLERECKEEQCSFEEAREIFKDAERTKLFWISYSDGDQCASSPCQNGGS
CKDQLQSYICFCLPAFEGRNCETHKDDQLICVNENGGCEQYCSDHTGTKRSCRCHEGYSL
LADGVSCTPTVEYPCGKIPILEKRNASKPQGRIVGGKVCPKGECPWQVLLLVNGAQLCGG
TLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTN
HDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVL
NVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTG
IVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP
Download FASTA Format
Synonyms
  • Coagulation factor VIIa
  • Coagulation factor VIIa (recombinant)
  • Coagulation factor VIIa (recombinant)-jncw
  • Eptacog alfa
  • Eptacog alfa (activated)
  • rFVIIa

Pharmacology

Indication

For treatment of hemorrhagic complications in hemophilia A and B.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Used in the treatment of bleeding episodes in hemophilia A or B. NovoSeven is recombinant Factor VIIa and, when complexed with tissue factor can activate coagulation Factor X to Factor Xa, as well as coagulation Factor IX to Factor IXa. Factor Xa, in complex with other factors, then converts prothrombin to thrombin, which leads to the formation of a hemostatic plug by converting fibrinogen to fibrin and thereby inducing local clotting.

Mechanism of action

NovoSeven activates the coagulation or clotting cascade by cleaving Factor IX and Factor X, which activates them and then leads to activation of thrombin and fibrin.

TargetActionsOrganism
UCoagulation factor XNot AvailableHumans
UTissue factor pathway inhibitorNot AvailableHumans
UVitamin K-dependent gamma-carboxylaseNot AvailableHumans
UCoagulation factor VIINot AvailableHumans
UTissue factorNot AvailableHumans
Absorption

Not Available

Volume of distribution
  • 121 ± 30 mL/kg [adults]
  • 153 ± 29 mL/kg [children]
  • 280 to 290 mL/kg [congenital Factor VII deficiency]
Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance
  • 33 - 37 mL/h x kg [healthy]
  • 1375 +/- 396 mL/hr [severe hemophilia A male children]
  • 57.3 +/- 9.5 mL/hr/kg [severe hemophilia A male children]
  • 2767 +/- 385 mL/hr [severe hemophilia A men]
  • 37.6 +/- 13.1 mL/hr/kg [severe hemophilia A men]
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Abciximab.
AcenocoumarolThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Acenocoumarol.
Alpha-1-proteinase inhibitorAlpha-1-proteinase inhibitor may increase the thrombogenic activities of Coagulation factor VIIa Recombinant Human.
AlteplaseThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Alteplase.
Aminocaproic acidThe risk or severity of adverse effects can be increased when Aminocaproic acid is combined with Coagulation factor VIIa Recombinant Human.
AncrodThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Ancrod.
AnistreplaseThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Anistreplase.
Antithrombin AlfaThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Antithrombin Alfa.
Antithrombin III humanThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Antithrombin III human.
ApixabanThe therapeutic efficacy of Coagulation factor VIIa Recombinant Human can be decreased when used in combination with Apixaban.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
NiastasePowder, for solution1.2 mg / vialIntravenousNovo Nordisk1999-08-052013-07-22Canada flag
NiastasePowder, for solution4.8 mg / vialIntravenousNovo Nordisk1999-08-052013-07-22Canada flag
NiastasePowder, for solution2.4 mg / vialIntravenousNovo Nordisk1999-08-052013-07-22Canada flag
Niastase RTKit; Powder, for solution1 mg / vialIntravenousNovo Nordisk2015-05-05Not applicableCanada flag
Niastase RTKit; Powder, for solution5 mg / vialIntravenousNovo Nordisk2010-08-25Not applicableCanada flag
Niastase RTKit; Powder, for solution8 mg / vialIntravenousNovo NordiskNot applicableNot applicableCanada flag
Niastase RTKit; Powder, for solution2 mg / vialIntravenousNovo Nordisk2010-08-05Not applicableCanada flag
Niastase RTKit; Powder, for solution2 mg / vialIntravenousNovo Nordisk2015-05-05Not applicableCanada flag
Niastase RTKit; Powder, for solution5 mg / vialIntravenousNovo Nordisk2015-05-05Not applicableCanada flag
Niastase RTKit; Powder, for solution8 mg / vialIntravenousNovo NordiskNot applicableNot applicableCanada flag

Categories

ATC Codes
B02BD08 — Coagulation factor viia
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
AC71R787OV
CAS number
102786-61-8

References

General References
  1. Blackshear PJ, Holloway PA, Alberti KG: Factors regulating amino acid release from extrasplanchnic tissues in the rat. Interactions of alanine and glutamine. Biochem J. 1975 Sep;150(3):379-87. [Article]
  2. Roberts HR, Monroe DM, White GC: The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004 Dec 15;104(13):3858-64. Epub 2004 Aug 24. [Article]
  3. Kenet G, Walden R, Eldad A, Martinowitz U: Treatment of traumatic bleeding with recombinant factor VIIa. Lancet. 1999 Nov 27;354(9193):1879. [Article]
  4. O'Connell KA, Wood JJ, Wise RP, Lozier JN, Braun MM: Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006 Jan 18;295(3):293-8. [Article]
  5. Mayer SA, Brun NC, Begtrup K, Broderick J, Davis S, Diringer MN, Skolnick BE, Steiner T: Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med. 2005 Feb 24;352(8):777-85. [Article]
  6. FDA Approved Drug Products: Sevenfact (coagulation factor VIIa (recombinant)-jncw) for intravenous use [Link]
  7. Health Canada Product Monograph: NiaStase RT (eptacog alfa (activated) ) powder for injection [Link]
UniProt
P08709
Genbank
M13232
KEGG Drug
D00172
KEGG Compound
C03378
PubChem Substance
46507544
RxNav
253149
PharmGKB
PA164748389
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Factor_VII

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentCongenital Hematological Disorder / Haemophilia A With Inhibitors / Haemophilia B With Inhibitors1
4CompletedTreatmentHemophilia A1
4CompletedTreatmentHereditary Factor VIII Deficiency Disease With Inhibitor1
4CompletedTreatmentPostpartum Haemorrhage (PPH)1
4RecruitingTreatmentHemophilia A With Inhibitors / Hemophilia B With Inhibitor1
3CompletedNot AvailableHemophilia A1
3CompletedTreatmentAcquired Bleeding Disorder / Cerebral Hemorrhage1
3CompletedTreatmentBurns1
3CompletedTreatmentCongenital Hematological Disorder / Haemophilia A With Inhibitors / Haemophilia B With Inhibitors1
3CompletedTreatmentFactor VII Deficiency1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Novo Nordisk Inc.
Dosage Forms
FormRouteStrength
Powder, for solutionIntravenous1.2 mg / vial
Powder, for solutionIntravenous2.4 mg / vial
Powder, for solutionIntravenous4.8 mg / vial
Kit; powder, for solutionIntravenous1 mg / vial
Kit; powder, for solutionIntravenous2 mg / vial
Kit; powder, for solutionIntravenous5 mg / vial
Kit; powder, for solutionIntravenous8 mg / vial
Injection, powder, for solutionIntravenous100 KIU
Injection, powder, for solutionIntravenous250 KIU
Injection, powder, for solutionIntravenous400 KIU
Injection, powder, for solutionIntravenous50 KIU
Injection, powder, for solutionIntravenous bolus
Injection, powder, lyophilized, for solutionIntravenous
Injection, powder, for solution
KitIntravenous1 mg/1mL
Injection, powder, lyophilized, for solutionIntravenous1 mg
InjectionIntravenous
Injection, powder, lyophilized, for solutionIntravenous2 mg
Injection, powder, lyophilized, for solutionIntravenous5 mg
Powder1 mg/ml
Prices
Unit descriptionCostUnit
Novoseven 1200 mcg vial1.64USD vial
Novoseven 2400 mcg vial1.64USD vial
Novoseven 4800 mcg vial1.64USD vial
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)58 °CPetersen, L.C. et al., Eur. J. Biochem 261: 124-129 (1999)
hydrophobicity-0.311Not Available
isoelectric point6.09Not Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Malinvaud G: [Reflections on the use of PPSB fraction (Prothrombin-proconvertin-Stuart factor-antihemophilic factor B)]. Transfusion (Paris). 1966;9(3):245-54. [Article]
  2. BLATRIX C, SOULIER JP: [Preparation of a fraction rich in prothrombin, proconvertin, Stuart factor and antihemophilic factor B (P.P.B. fraction)]. Pathol Biol (Paris). 1959 Dec;7:2477-86. [Article]
  3. HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6. [Article]
  4. GAERTNER H, CAEN J: [FUNCTIONAL RELATION BETWEEN ERYTHROPLASTIN (ERYTHROCYTE COAGULANT FACTOR) AND PLASMA FACTORS: PROACCELERIN (V), PROCONVERTIN (VII) AND STUART FACTOR(X)]. Acta Physiol Pol. 1964 Mar-Apr;15:237-43. [Article]
  5. DIDISHEIM P, LOEB J, BLATRIX C, SOULIER JP: Preparation of a human plasma fraction rich in prothrombin, proconvertin, Stuart factor, and PTC and a study of its activity and toxicity in rabbits and man. J Lab Clin Med. 1959 Feb;53(2):322-30. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type endopeptidase inhibitor activity
Specific Function
Inhibits factor X (X(a)) directly and, in a Xa-dependent way, inhibits VIIa/tissue factor activity, presumably by forming a quaternary Xa/LACI/VIIa/TF complex. It possesses an antithrombotic action...
Gene Name
TFPI
Uniprot ID
P10646
Uniprot Name
Tissue factor pathway inhibitor
Molecular Weight
35014.835 Da
References
  1. Mine S, Yamazaki T, Miyata T, Hara S, Kato H: Structural mechanism for heparin-binding of the third Kunitz domain of human tissue factor pathway inhibitor. Biochemistry. 2002 Jan 8;41(1):78-85. [Article]
  2. Narita M, Bu G, Olins GM, Higuchi DA, Herz J, Broze GJ Jr, Schwartz AL: Two receptor systems are involved in the plasma clearance of tissue factor pathway inhibitor in vivo. J Biol Chem. 1995 Oct 20;270(42):24800-4. [Article]
  3. Stassens P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP: Anticoagulant repertoire of the hookworm Ancylostoma caninum. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2149-54. [Article]
  4. Lee AY, Vlasuk GP: Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Intern Med. 2003 Oct;254(4):313-21. [Article]
  5. Hansen CB, Pyke C, Petersen LC, Rao LV: Tissue factor-mediated endocytosis, recycling, and degradation of factor VIIa by a clathrin-independent mechanism not requiring the cytoplasmic domain of tissue factor. Blood. 2001 Mar 15;97(6):1712-20. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Gamma-glutamyl carboxylase activity
Specific Function
Mediates the vitamin K-dependent carboxylation of glutamate residues to calcium-binding gamma-carboxyglutamate (Gla) residues with the concomitant conversion of the reduced hydroquinone form of vit...
Gene Name
GGCX
Uniprot ID
P38435
Uniprot Name
Vitamin K-dependent gamma-carboxylase
Molecular Weight
87560.065 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Bouwman CA, Van Dam E, Fase KM, Koppe JG, Seinen W, Thijssen HH, Vermeer C, Van den Berg M: Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin or 2,2',4,4',5,5'-hexachlorobiphenyl on vitamin K-dependent blood coagulation in male and female WAG/Rij-rats. Chemosphere. 1999 Feb;38(3):489-505. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Serine-type peptidase activity
Specific Function
Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, o...
Gene Name
F7
Uniprot ID
P08709
Uniprot Name
Coagulation factor VII
Molecular Weight
51593.465 Da
References
  1. Perera L, Darden TA, Pedersen LG: Probing the structural changes in the light chain of human coagulation factor VIIa due to tissue factor association. Biophys J. 1999 Jul;77(1):99-113. [Article]
  2. Shapiro A: Inhibitor treatment: state of the art. Semin Hematol. 2001 Oct;38(4 Suppl 12):26-34. [Article]
  3. Shapiro A: Inhibitor treatment: state of the art. Dis Mon. 2003 Jan;49(1):22-38. [Article]
  4. Siddiqui MA, Scott LJ: Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders. Drugs. 2005;65(8):1161-77. [Article]
  5. Rizoli SB, Chughtai T: The emerging role of recombinant activated Factor VII (rFVIIa) in the treatment of blunt traumatic haemorrhage. Expert Opin Biol Ther. 2006 Jan;6(1):73-81. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protease binding
Specific Function
Initiates blood coagulation by forming a complex with circulating factor VII or VIIa. The [TF:VIIa] complex activates factors IX or X by specific limited protolysis. TF plays a role in normal hemos...
Gene Name
F3
Uniprot ID
P13726
Uniprot Name
Tissue factor
Molecular Weight
33067.3 Da
References
  1. HERMANSKY F, VITEK J: The role of proconvertin and Stuart factor in the inactivation of tissue thromboplastin by serum. Experientia. 1960 Oct 15;16:455-6. [Article]
  2. Rogers KS, Barton CL, Benson PA, Green RA: Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma. Am J Vet Res. 1992 Apr;53(4):580-4. [Article]
  3. Christensen NJ: Measurements of some blood clotting factors using a centrifugal analyser (Multistat III). Scand J Clin Lab Invest. 1983 Oct;43(6):521-6. [Article]

Drug created on June 13, 2005 13:24 / Updated on July 24, 2021 14:57